- ¹ Investigating associations between physical
- ² multimorbidity clusters and subsequent depression:
- ³ cluster and survival analysis of UK Biobank data
- 4
- 5 Lauren Nicole DeLong^{1,*}, Kelly Fleetwood², Regina Prigge², Paola Galdi¹, Bruce Guthrie³, and Jacques
- 6 D. Fleuriot^{1,3}
- 7
- 8 1 Artificial Intelligence and its Applications Institute, School of Informatics, University of Edinburgh,
- 9 Edinburgh, UK
- 10 2 Usher Institute, University of Edinburgh, Edinburgh, UK
- 11 3 Advanced Care Research Centre, Usher Institute, University of Edinburgh, Edinburgh, UK
- 12
- 13 * <u>L.N.DELONG@sms.ed.ac.uk</u>
- 14
- 15

16 Abstract

17 Background

18 Multimorbidity, the co-occurrence of two or more conditions within an individual, is a growing challenge

- 19 for health and care delivery as well as for research. Combinations of physical and mental health
- 20 conditions are highlighted as particularly important. The aim of this study was to investigate associations
- 21 between physical multimorbidity and subsequent depression.

22 Methods and Findings

23 We performed a clustering analysis upon physical morbidity data for UK Biobank participants aged 37-73

years at baseline data collection between 2006-2010. Of 502,353 participants, 142,005 had linked general

25 practice data with at least one physical condition at baseline. Following stratification by sex (77,785

women; 64,220 men), we used four clustering methods (agglomerative hierarchical clustering, latent class

analysis, *k*-medoids and *k*-modes) and selected the best-performing method based on clustering metrics.

28 We used Fisher's Exact test to determine significant over-/under-representation of conditions within each

29 cluster. Amongst people with no prior depression, we used survival analysis to estimate associations

30 between cluster-membership and time to subsequent depression diagnosis.

31 The *k*-modes models consistently performed best, and the over-/under-represented conditions in the

32 resultant clusters reflected known associations. For example, clusters containing an overrepresentation of

cardiometabolic conditions were amongst the largest clusters in the whole cohort (15.5% of participants,

- 34 19.7% of women, 24.2% of men). Cluster associations with depression varied from hazard ratio (HR)
- 35 1.29 (95% confidence interval (CI) 0.85-1.98) to HR 2.67 (95% CI 2.24-3.17), but almost all clusters

36 showed a higher association with depression than those without physical conditions.

37 Conclusions

- 38 We found that certain groups of physical multimorbidity may be associated with a higher risk of
- 39 subsequent depression. However, our findings invite further investigation into other factors, like social
- 40 ones, which may link physical multimorbidity with depression.

42 Introduction

Multimorbidity, the simultaneous occurrence of two or more long-term conditions in an individual is increasingly common as populations age, and it challenges existing health systems ^{1,2}. Multimorbidity is more common with increasing age, in women and in the less affluent ^{3,4}. Studying the co-occurrence of multiple long-term conditions in the same individual has the potential to inform understanding of disease causation and support planning of current and future health and care services ^{5–7}.

Depression affects millions of people worldwide ^{8,9} and is ranked by the World Health 48 Organization as one of the most burdensome diseases ^{9,10}. There is strong evidence that depression co-49 occurs with other mental health disorders ^{11,12}, and several ongoing studies aim to identify potential shared 50 mechanisms ^{11,13}. However, previous studies have also found depression to be more common in people 51 with particular chronic physical illnesses, such as cardiovascular disease ¹⁴, multiple sclerosis ¹⁵, and 52 inflammatory bowel disease ¹⁶. Physical ill-health might cause depression because it creates psychological 53 54 disturbance through 'biographical disruption' that threatens a sense of identity, or because of impact on physical or social function. Alternatively, physical conditions may cause depression through intermediate 55 biological processes, like inflammation ^{15,17}, in which case we might expect that different combinations or 56 patterns of physical conditions would be more strongly associated with depression than others. 57 Several studies have used cluster analyses to identify common patterns of physical conditions ^{18–21}, 58 typically using one method, such as agglomerative hierarchical clustering 18,19,22 , k-medoids 20,23 , Latent 59 Class Analysis $^{21,24-26}$, or *k*-means approaches $^{27-30}$. Additionally, since morbidity data is binary (a person 60 61 has a condition or does not), some common clustering methods are inappropriate since they use similarity measures incompatible with categorical data ^{18,31}. Therefore, the aim of this study was to explore and 62 63 compare the use of four independent clustering methods appropriate for binary data and to examine 64 whether certain groups of physical conditions are associated with the subsequent diagnosis of depression.

66 Materials and methods

⁶⁷ Data selection and pre-processing

68	We used data from UK Biobank ³² . Participants aged 37-73 years attended a baseline assessment during
69	2006-2010 which collected data on demography, lifestyle habits, health conditions, and a range of
70	physical and laboratory measurements. Participants provided written informed consent for linkage to
71	national datasets including general practice (GP) (primary care), hospital, cancer registry and death
72	records ³² . The UK Biobank has ethical approval from the NHS North West Research Ethics Committee
73	(reference: 21/NW/0157).
74	To robustly ascertain a broad range of long-term conditions, our study population included
75	participants with a continuous GP record from at least a year before to at least one day beyond their
76	baseline assessment. We excluded records from the UKB extract of the Vision practice management
77	system in England because the extraction process excluded participants who died prior to data extraction.
78	We also excluded participants who withdrew from the study (Supplementary Fig. 1).
79	We ascertained the presence of depression and 69 long-term physical health conditions at
80	baseline using data from the baseline visit and from linked GP, hospital, and cancer registry records based
81	on previously published lists ^{33,34} (Supplementary Table 1). The UK National Health Service limits
82	registration to one practice at a time, and GP records transfer between practices so should capture an
83	individual's entire medical history. However, available hospital and cancer registry records began at
84	different times for England, Wales and Scotland. Therefore, we used all GP records up to baseline

assessment date, and to be consistent across countries, we used hospital and cancer registry records within

86 eight years before baseline assessment date. We used published codelists to identify diagnoses from GP

87 records using Read V2 and CTV3 diagnosis codes, hospital records using ICD-10 diagnosis codes and

88 OPCS-4 procedure codes, and cancer registry records using ICD-10 codes ³⁴. We similarly ascertained

depression during follow-up using information from GP, hospital and death records. Eligible participants
with no history of depression prior to baseline were followed up to the earliest of depression diagnosis,
death or the end of their available GP or hospital records.

92

93 Models and metrics

We explored the suitability of four methods (k-modes ^{35,36}, k-medoids ²³, Latent Class Analysis 94 (LCA)²⁴, and agglomerative hierarchical clustering (AHC)²² (Supplementary Appendix 1)) to cluster all 95 96 participants based on binary features denoting the absence/presence of the 69 baseline physical conditions. Participants with no physical conditions at baseline were excluded from the clustering 97 analysis. We additionally clustered separately for men (all 69 conditions) and women (67 conditions since 98 99 erectile dysfunction and hyperplasia of the prostate are only found in men), as well as in the whole population, because of known sex differences in patterns of individual morbidities and multimorbidity 100 37,38 101

To select the number of clusters for each method, we used various heuristics, including the elbow method on a scree plot ³⁹ for both *k*-modes and *k*-medoids, the minimal Bayesian Information Criterion ⁴⁰ for LCA, and Hamming distance ⁴¹ for AHC. To assess suitability and performance of these clustering methods, we used three performance metrics (Calinski and Harabasz score ⁴², Davies-Bouldin score ⁴³, and Silhouette score ⁴⁴ (Supplementary Appendix 1)), which are appropriate for unsupervised clustering. Since *k*-modes and LCA are sensitive to differences in initialization ^{24,45}, we repeated them five times and compared with other models using the mean and standard deviation across the five experiments.

109 Thereafter, we used two metrics to analyze over- and under-representation of conditions in each 110 cluster. We designed one metric, the *adjusted relative frequency (ARF)* to measure the magnitude of over-111 or under-represented conditions within a cluster, relative to prevalence in the whole cohort. For each 112 condition, ARF is calculated as:

113
$$adjusted relative frequency (ARF) = \frac{\% \text{ with condition in cluster}}{\% \text{ with condition in the cohort}}$$

114 An ARF of exactly one indicates that the condition occurs at the same relative frequency as it does in the

entire cohort, and values greater or less than one indicate over- and under-representation, respectively.

116 We used Fisher's Exact Test (two-sided, α =0.05) to evaluate whether over- or under-representation of a

117 condition in each cluster was statistically significant, using a Bonferroni correction to account for

118 multiple testing ^{46–48}. Finally, we visualised and compared statistically significant results on a *bubble*

119 *heatmap* (Supplementary Appendix 2). To allow others to conduct similar cluster analyses, we made the

120 code available as a software package (<u>https://github.com/laurendelong21/clusterMed</u>).

121

122 Survival analysis to predict depression diagnosis

Using participants without a record of depression at baseline, we applied Cox regression models ⁴⁹ to 123 evaluate time to depression diagnosis by condition cluster, accounting for death as a competing risk ⁵⁰. 124 Participants with no physical conditions at baseline were included as the reference group. We ran separate 125 models for the whole cohort and for men and women separately, examining associations between cluster 126 127 membership and subsequent depression. All models were adjusted for baseline age, ethnicity, country of 128 residence and deprivation. The model for the whole cohort was additionally adjusted for sex. Baseline age 129 was included in the models as a continuous variable; all other variables were categorical. Ethnicity was 130 self-reported at baseline, and we categorized it into five groups (Black, Mixed, South Asian, White, and any other ethnic group ⁵¹). Country of residence (England, Wales or Scotland) and area-based deprivation, 131 measured by the Townsend Deprivation Index 52, were derived from participants' home addresses at 132 baseline. We divided the Townsend Deprivation Index into deciles within the entire UK Biobank cohort. 133 A small number of participants (368 women and 435 men) who were missing data on ethnicity, country 134 135 or deprivation were excluded from the survival analyses.

136 Results

137 Performance metrics across various clustering methods

There were 140,956 participants (73,036 women and 67,920 men) with at least one physical condition at
baseline who were included in the clustering analysis (Supplementary Fig. 1). Performance metrics for
each of the four methods explored are reported in Table 1.

141 Models based on AHC consistently achieved the poorest Calinski and Harabasz, and Davies-Bouldin scores in all three cohorts. Models based on LCA had better metrics than AHC-based models, with 142 143 particularly high Calinski and Harabasz scores, but the Davies-Bouldin scores were consistently worse in comparison to k-modes or k-medoids based models. In contrast, the best Davies-Bouldin scores were 144 achieved by the k-modes and k-medoids based models. However, since the Davies-Bouldin score assesses 145 146 similarity between the most similar clusters, scores may be optimistic when several clusters only contain a 147 single (or very few) participant(s). This was the case for the k-medoids models for the whole and men-148 only cohorts. The presence of singleton clusters is also concurrent with a larger number of total clusters. Specifically, all three models based on k-modes discovered eight clusters, all models using AHC 149 discovered ten clusters, and all models using LCA discovered five or six clusters. In contrast, the k-150 151 medoids models discovered 25 clusters for the whole population (17 only had one participant, six for women-only (no singletons), and 13 for men-only (seven singletons) (Table 1). Therefore, while k-152 153 medoids models had comparable Davies-Bouldin scores to k-modes models, the results were less 154 informative and consistent. For each cohort, we therefore selected the best performing k-modes model with the highest Calinski and Harabasz score among the five independent runs. 155

Cohort	Clustering	Calinski and	Davies-Bouldin	Silhouette	No. of	No. of	Median	(Min-max.)
	method	Harabasz score	score (lower is	score (higher	clusters	singleton	participants /	participants per
		(higher is better)	better)	is better)		clusters	cluster	cluster
Whole	LCA	5567.79 ± 175.06	3.80 ± 0.34	0.08 ± 0.03	6	0	17203.5	(6816 - 57564)
	AHC	628.39	4.38	0.09	10	0	2495.5	(11 - 110366)
	<i>k</i> -medoids	1270.00	2.48	0.08	25	17	1	(1 - 55553)
	<i>k</i> -modes	6079.53 ± 1228.07	2.43 ± 0.16	0.17 ± 0.02	8	0	14954.5	(974 - 39601)
Women-	LCA	4098.56 ± 5.23	3.53 ± 0.00	0.15 ± 0.00	5	0	15794	(2373 - 30529)
only	АНС	524.62	4.82	0.04	10	0	1374.5	(2 - 47728)
	<i>k</i> -medoids	3672.43	2.60	0.14	6	0	9472	(3942 - 28757)
	<i>k</i> -modes	3456.82 ± 555.59	2.36 ± 0.10	0.16 ± 0.04	8	0	9233.5	(562 - 22787)
Men-only	LCA	3134.68 ± 91.36	3.52 ± 0.02	0.10 ± 0.00	5	0	13868	(6827 - 16448)
	АНС	274.95	4.18	0.20	10	0	1709	(7 - 27353)
	<i>k</i> -medoids	1225.80	2.17	0.11	13	7	1	(1 - 25595)
	<i>k</i> -modes	2779.42 ± 463.66	2.35 ± 0.07	0.15 ± 0.03	8	0	8545.5	(649 - 15532)

156 Table 1. Performance metrics, number of clusters, and cluster sizes across four clustering methods.

157 Results for LCA and k-modes are reported as average \pm standard deviation across five independent models.

¹⁵⁸ Differential representation of physical conditions within *k*-modes

159 clusters

160	Many of the significantly over-represented conditions within several clusters aligned with body
161	systems (Fig. 1) and we therefore used clinical judgement to name the clusters according to the systems or
162	conditions which were most prominent (Supplementary Tables 2-5). The four largest clusters in whole
163	cohort are <i>Mixed including cancer</i> (27.9% of participants in the cohort), <i>Healthy</i> + <i>Rhinitis</i> (22.2%),
164	Cardiovascular disease (CVD) + diabetes (15.5%), and Very extensive morbidity (12.5%). For women,
165	the four largest clusters are <i>Mixed including cancer</i> (29.3%), <i>CVD</i> + <i>diabetes</i> (19.7%), <i>Musculoskeletal</i>
166	(MSK) (16.4%), and Healthy + Rhinitis (15.9%). Finally, for men, the four largest clusters are CVD +
167	diabetes (24.2%), Mixed including cancer (20.8%), MSK + others (19.1%), and Healthy + Rhinitis
168	(17.2%) (Fig. 2, Table 2).
169	Of the remaining clusters, there were some similarities across all three cohorts (e.g. Respiratory
170	clusters). Generally, clusters with more participants also tended to have fewer conditions per participant
171	(Fig. 2). For example, the Mixed including cancer clusters had the lowest mean conditions per participant
172	(whole: 1.77; women: 1.75; men: 1.62). Such clusters may serve as "miscellaneous" categories for
173	participants with condition profiles that are not easily grouped and/or people with one dominant
174	condition. However, there were also differences. For example, there were clusters which only appeared in
175	the whole population (Migraine) and clusters which only appeared in the sex-stratified cohorts (Digestive
176	and MSK clusters).

Fig. 1. Bubble heatmap shows under- and over-represented conditions in each cluster from the *k*modes derived models



179 Clusters
 180 Magnitude (adjusted ARF values (*Suppl. Appendix 2*)) is an ordinal representation of the level of over- or under-representation
 181 (e.g., a red bubble of magnitude 2.0 indicates that a condition is more overrepresented than a red bubble of magnitude 1.5).

182 Fig. 2. Cluster sizes and condition counts.



183

k-modes cluster label

k-modes cluster label

184

186 Subsequent incident depression per identified cluster

187	Analysis of time to incident depression diagnosis included 141,001 participants (73,036 women
188	and 67,920 men), excluding 30,770 participants with a history of depression at baseline (20,592 women
189	and 10,178 men). In addition to participants included in the clustering analysis, this analysis also included
190	30,551 participants with no physical conditions at baseline (16,238 women and 14,313 men)
191	(Supplementary Fig. 1). During an average follow-up of 6.8 years, 5,904 (4.2%) participants, including
192	3,574 (4.9%) women and 2,330 (3.4%) men, had a new depression diagnosis. Generally, participants with
193	physical conditions at baseline had a higher rate of subsequent depression than participants with no
194	physical conditions at baseline (Table 2, Supplementary Fig. 3).
195	There were several consistencies across cohorts. The Very extensive morbidity clusters were the
196	most strongly associated with depression in all three cohorts (whole: HR 2.42, 95% CI 2.17-2.69; women:
197	HR 2.67, 95% CI 2.24-3.17; men: HR 2.65, 95% CI 2.22-3.18). Additionally, the <i>Healthy</i> + <i>rhinitis</i>
198	(whole: HR 1.59, 95% CI 1.46-1.75; women: HR 1.48, 95% CI 1.30-1.67; men: HR 1.50, 95% CI 1.29-
199	1.75) and Mixed including cancer (whole: HR 1.62, 95% CI 1.48-1.77; women: HR 1.63, 95% CI 1.46-
200	1.82; men: HR 1.60, 95% CI 1.38-1.86) clusters were generally the most weakly associated. Finally,
201	association with depression also appeared to increase with the number of conditions per participant (Fig.
202	3). However, there were some exceptions; for example, the whole cohort's <i>Macular degeneration</i> +
203	diabetes cluster had the fourth highest mean number of conditions (3.09), but was only weakly associated
204	with depression (HR 1.29, 95% CI 0.85-1.98).

205

Cohort	Cluster Label	No. (%) of	Mean no. of	Hazard ratio
		participants	conditions per	(95% CI)
		in cluster	participant in	
Whole cohort	Voru outongius marhiditu	17767 (12.5)		2 42 (2 17 2 60)
Whole conoit	Very extensive morbidity	17707 (12.3)	4.30	2.42(2.17, 2.09)
	Migraine	12142 (8.6)	3.23	1.96 (1.75, 2.19)
	Respiratory	11937 (8.4)	4.00	1.95 (1.74, 2.18)
	Respiratory w/o other	6118 (4.3)	2.29	1.86 (1.62, 2.15)
	CVD + diabetes	21989 (15.5)	2.38	1.78 (1.61, 1.97)
	Mixed including cancer	39601 (27.9)	1.77	1.62 (1.48, 1.77)
	Healthy + rhinitis	31477 (22.2)	2.58	1.59 (1.46, 1.75)
	Macular degeneration + diabetes	974 (0.7)	3.09	1.29 (0.85, 1.98)
Women-only	Very extensive morbidity	4420 (5.7)	5.69	2.67 (2.24, 3.17)
	Extensive morbidity	3549 (4.6)	4.61	2.56 (2.12, 3.10)
	Respiratory	6133 (7.9)	3.72	1.93 (1.67, 2.23)
	Digestive	562 (0.7)	4.49	1.83 (1.14, 2.93)
	MSK	12715 (16.4)	2.85	1.81 (1.58, 2.07)
	CVD + diabetes	15285 (19.7)	2.70	1.71 (1.52, 1.94)
	Mixed including cancer	22787 (29.3)	1.75	1.63 (1.46, 1.82)
	Healthy + rhinitis	12334 (15.9)	2.02	1.48 (1.30, 1.67)
Men-only	Very extensive morbidity	6023 (9.4)	4.30	2.65 (2.22, 3.18)
	MSK + others	12287 (19.1)	3.46	2.50 (2.15, 2.91)
	Respiratory + gout + male			
	genitourinary	649 (1.0)	5.23	2.25 (1.43, 3.53)
	Digestive	2281 (3.6)	3.47	2.06 (1.60, 2.66)
	CVD + diabetes	15532 (24.2)	2.71	1.90 (1.65, 2.20)
	CVD + CKD + gout	3039 (4.7)	3.77	1.87 (1.47, 2.38)
	Mixed including cancer	13341 (20.8)	1.62	1.60 (1.38, 1.86)
	Healthy + rhinitis	11068 (17.2)	2.08	1.50 (1.29, 1.75)

207 Table 2. Hazard ratios per cluster for the development of subsequent depression.

All models were adjusted for baseline age, ethnicity, country of residence, and deprivation.



209 Fig. 3. Risk of subsequent depression by mean number of physical conditions.

Each point represents a cluster value. Error bars represent a 95% confidence interval.

212 Discussion

213 Summary of findings

214 This study systematically explored clustering of physical health conditions using four methods

appropriate for binary data (*k*-modes 35,36 , *k*-medoids 23 , Latent Class Analysis 24 , and agglomerative

216 hierarchical clustering (AHC)²²). *K*-modes performed best, and the clusters identified were reasonably

217 interpretable and often aligned with known associations between conditions. People with any physical

condition at baseline were generally more likely to develop depression than people without any physical

condition. There was some variation in this association by cluster which may be at least partly driven by

220 differences in the mean number of physical conditions in each cluster.

221 Comparison with other studies

222 Existing studies of morbidity clustering typically apply a single method. One study compared LCA to a

223 Bayesian, network-based approach, but used age and admission type, rather than conditions alone, to

drive cluster formation 53. Two other studies explored AHC and k-means in the same dataset, but chose k-

means on the basis of AHC being too computationally intensive rather than based on performance ^{27,28}.

Additionally, despite the use of *k*-means 54 by several multimorbidity studies $^{27-30}$, it typically relies upon

227 Euclidean distance as its similarity measure ³¹, which is unsuitable for binary data ¹⁸. Other

228 multimorbidity studies have used *k*-means *after* a Multiple Correspondence Analysis ^{55,56}, which

represents categorical features as a low-dimensional Euclidean space ^{29,30}. While this transforms the data

230 features into an appropriate format for *k*-means, it also manipulates the data based on their pairwise co-

231 occurrences, which may not be appropriate for every dataset.

This study finds that almost all physical morbidity clusters are associated with higher risk of subsequentdepression than the group with no physical conditions at baseline. Although the strength of association

varied by cluster, this seemed to be partly explained by the mean number of conditions in the cluster. This

is consistent with a similar study ²⁹ which found associations between severe mental illness and a higher

number of physical conditions. Another similar study, which aimed to identify groups of physical
conditions associated with incident depression within a Taiwanese cohort, also found that social factors
played a role on the risk of subsequent depression diagnosis ²¹. Specifically, they found that amongst four *Cardiometabolic, Arthritis-cataract, Multimorbidity,* and *Relatively healthy* clusters, those within the *Arthritis-cataract* and *Multimorbidity* clusters had significantly higher risk of depression than healthy
individuals. However, this association was attenuated for participants who engaged in social activities,
including a job, volunteer experience, or community activities ²¹.

243 Strengths and limitations

244 Strengths of this study include the analysis of a large dataset which records morbidities in both baseline 245 research data and linked routine data, as well as the inclusion of a wide set of morbidities recommended by a recent consensus study ⁵⁷. Notably, this study is unique for its implementation and comparison 246 247 between four clustering methods appropriate for binary data. A limitation is that the data are collected 248 from volunteers who are generally more affluent than the UK average, and people from ethnic minorities 249 are somewhat under-represented ⁵⁸. Additionally, there is no standard way to evaluate the validity of 250 identified clusters, although the observed clusters do include several known clinical associations. 251 Consequently, this warrants further validation studies in other datasets to explore reproducibility of cluster solutions. 252

253 Implications for research

Many previous studies of morbidity clustering do not provide much information about which conditions are over or under-represented in clusters, which leaves readers relying solely on author-chosen cluster labels for interpretation ^{19,21}. For example, it is common for other studies to identify a 'cardiometabolic' cluster ²¹ and the *CVD* + *diabetes* cluster in our study was amongst the three largest clusters in all three cohorts. However, it is not straightforward to compare clusters across studies because of considerable variation in the conditions included in analysis, and because many clustering studies do not provide

260 detailed information about the nature of identified clusters. Key implications are that clustering studies should be more consistent in the choice of conditions to include (and, at a minimum, follow consensus 261 recommendations ⁵⁷). Additionally, they should report the nature of clusters to help understand them 262 263 beyond their high-level labels (by, for example, visualizing the prevalence of individual conditions in each cluster alongside over/under representation). We believe that our Adjusted Relative Frequency 264 265 (ARF) measure with visualization in a bubble heatmap demonstrates one way to do this. However, there 266 is a need for multimorbidity researchers to develop improved and consistent cluster visualizations and 267 explanations to facilitate interpretation and to enhance clinical utility.

268 Morbidity clustering studies also typically use one clustering method, but there is no single clustering 269 method which is likely to be optimal for every dataset. We therefore believe that clustering studies should 270 more systematically explore different methods and make explicit how they choose the best method for 271 their datasets and purposes. To encourage similar systematic comparison of different cluster methods, we 272 have provided access to our code (https://github.com/laurendelong21/clusterMed). Many studies also cluster the entire population which is likely not sensible given the very different incidence and prevalence 273 274 of disease with age and, to a lesser extent, sex and ethnicity. In this analysis, study participants were 275 mostly middle-aged (so we did not further stratify by age) and overwhelmingly white, but we found some 276 differences in the clusters identified in the whole population versus women or men separately. Although 277 whole population clustering may be appropriate in some circumstances, reporting of clusters stratified by 278 age and sex (and ethnicity if the data permits) would be valuable to explore how clustering varies by 279 demographic characteristics.

Finally, further research to better understand why physical multimorbidity is associated with subsequent
depression is needed. The general trend between increased risk of subsequent depression and mean
number of conditions suggests a social explanation: suffering more conditions may more strongly
interrupt one's life or sense of self. However, the relationship between depression and physical conditions

- is very likely bidirectional and longitudinal research which better examines how the two interact over a
- 285 lifetime would be valuable.

286 Conclusions

- 287 Using the best performing of four different clustering methods, this study identified several
- 288 multimorbidity clusters which align with known clinical associations. Association with depression varied
- between clusters, but this may be partly driven by differences in the number of conditions. More research
- is needed to better understand the mechanisms underlying such associations.
- 291

292 Data Availability

- 293 The UK Biobank data is not openly available to protect the rights of participants. Researchers can register
- 294 for access here: <u>https://www.ukbiobank.ac.uk/enable-your-research/register</u> .

295 Code Availability

296 Corresponding code is available at <u>https://github.com/laurendelong21/clusterMed</u>.

297 Competing Interests

298 The authors declare no competing interests.

299 Author Contributions

- 300 All authors contributed to writing the manuscript. L.N.D. and K.F. conducted the analyses and made the
- 301 figures. L.N.D. and P.G. wrote the software. K.F. and R.P. processed and prepared the data. J.D.F. and
- **302** B.G. designed and supervised the study.

303 Acknowledgments

- 304 This work was co-funded by the Medical Research Council and the National Institute for Health Research
- 305 (grant number MC/S028013), and the NIHR AIM-CISC programme (grant number NIHR202639). The
- 306 views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of
- 307 Health and Social Care. The study was conducted using the UK Biobank Resource under application

308 number 57213.

- 309 LND is individually funded by a Global Informatics Scholarship from the School of Informatics at the
- 310 University of Edinburgh. The School of Informatics had no role in study design, data collection and
- analysis, decision to publish, or preparation of the manuscript.
- 312 The authors would like to thank the UK Biobank participants and the UK Biobank staff for their
- 313 contributions to this study. The authors would like to thank the public members of our advisory board, Dr
- Paul Kelly and Pat Watson, for providing thoughtful feedback throughout our project. This work has
- made use of the resources provided by the Edinburgh Compute and Data Facility (ECDF)
- 316 (<u>http://www.ecdf.ed.ac.uk/</u>).

318 References

- 319 1. Skou, S. T. *et al.* Multimorbidity. *Nat Rev Dis Primers* **8**, 1–22 (2022).
- Harrison, C. *et al.* Comorbidity versus multimorbidity: Why it matters. *Journal of Multimorbidity and Comorbidity* vol. 11 2633556521993993 Preprint at (2021).
- Fortin, M., Stewart, M., Poitras, M.-E., Almirall, J. & Maddocks, H. A Systematic Review of
 Prevalence Studies on Multimorbidity: Toward a More Uniform Methodology. *The Annals of Family Medicine* 10, 142–151 (2012).
- Barnett, K. *et al.* Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *The Lancet* 380, 37–43 (2012).
- Swain, S., Sarmanova, A., Coupland, C., Doherty, M. & Zhang, W. Comorbidities in
 Osteoarthritis: A systematic review and meta-analysis of observational studies. *Arthritis Care Res (Hoboken)* 72, 991–1000 (2020).
- Alexander, K. P. *et al.* Outcomes of apixaban versus warfarin in patients with atrial fibrillation and
 multi-morbidity: Insights from the ARISTOTLE trial. *Am Heart J* 208, 123–131 (2019).
- 332 7. Marrie, R. A. Comorbidity in multiple sclerosis: Past, present and future. *Clinical and*333 *Investigative Medicine* 42, E5–E12 (2019).
- Pitsillou, E. *et al.* The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression. *Mol Biol Rep* 47, 753–770 (2020).
- 336 9. Kraus, C., Kadriu, B., Lanzenberger, R., Zarate Jr, C. A. & Kasper, S. Prognosis and improved
 337 outcomes in major depression: a review. *Transl Psychiatry* 9, 1–17 (2019).
- 338 10. Malhi, G. S. & Mann, J. J. Depression. *The Lancet* **392**, 2299–2312 (2018).
- 339 11. Goodwin, G. M. The overlap between anxiety, depression, and obsessive-compulsive disorder.
 340 *Dialogues Clin Neurosci* (2022).
- Rao, S. & Broadbear, J. Borderline personality disorder and depressive disorder. *Australasian Psychiatry* 27, 573–577 (2019).
- 13. Gold, S. M. et al. Comorbid depression in medical diseases. Nat Rev Dis Primers 6, 1–22 (2020).
- 344 14. Shao, M. *et al.* Depression and cardiovascular disease: Shared molecular mechanisms and clinical
 345 implications. *Psychiatry Res* 285, 112802 (2020).
- Riemer, F. *et al.* Microstructural changes precede depression in patients with relapsing-remitting
 Multiple Sclerosis. *Communications Medicine* 3, 90 (2023).
- Marrie, R. A., Graff, L. A., Fisk, J. D., Patten, S. B. & Bernstein, C. N. The relationship between
 symptoms of depression and anxiety and disease activity in IBD over time. *Inflamm Bowel Dis* 27, 1285–1293 (2021).

351 352 353	17.	Davyson, E. <i>et al.</i> Metabolomic Investigation of Major Depressive Disorder Identifies a Potentially Causal Association With Polyunsaturated Fatty Acids. <i>Biol Psychiatry</i> 94 , 630–639 (2023).
354 355 356	18.	Cornell, J. E. <i>et al.</i> Multimorbidity Clusters: Clustering Binary Data From Multimorbidity Clusters: Clustering Binary Data From a Large Administrative Medical Database. <i>Applied Multivariate Research</i> 12 , 163 (2009).
357 358	19.	Bisquera, A. <i>et al.</i> Identifying longitudinal clusters of multimorbidity in an urban setting: A population-based cross-sectional study. <i>The Lancet Regional Health - Europe</i> 3 , 100047 (2021).
359 360	20.	Robertson, L. <i>et al.</i> Identifying multimorbidity clusters in an unselected population of hospitalised patients. <i>Sci Rep</i> 12 , 5134 (2022).
361 362 363	21.	Ho, HE., Yeh, CJ., Cheng-Chung Wei, J., Chu, WM. & Lee, MC. Association between multimorbidity patterns and incident depression among older adults in Taiwan: the role of social participation. <i>BMC Geriatr</i> 23 , 177 (2023).
364 365	22.	Sasirekha, K. & Baby, P. Agglomerative hierarchical clustering algorithm-a. <i>International Journal of Scientific and Research Publications</i> 83 , 83 (2013).
366 367	23.	Jin Xin and Han, J. K-Medoids Clustering. <i>Encyclopedia of Machine Learning</i> 564–565 (2010) doi:10.1007/978-0-387-30164-8_426.
368 369	24.	Weller, B. E., Bowen, N. K. & Faubert, S. J. Latent class analysis: a guide to best practice. <i>Journal of Black Psychology</i> 46 , 287–311 (2020).
370 371 372	25.	Hall, M. <i>et al.</i> Multimorbidity and survival for patients with acute myocardial infarction in England and Wales: Latent class analysis of a nationwide population-based cohort. <i>PLoS Med</i> 15 , e1002501 (2018).
373 374 375	26.	Eto, F. <i>et al.</i> Ethnic differences in early onset multimorbidity and associations with health service use, long-term prescribing, years of life lost, and mortality: A cross-sectional study using clustering in the UK Clinical Practice Research Datalink. <i>PLoS Med</i> 20 , e1004300 (2023).
376 377	27.	Ioakeim-Skoufa, I. <i>et al.</i> Multimorbidity Clusters in the Oldest Old: Results from the EpiChron Cohort. <i>Int J Environ Res Public Health</i> 19 , 10180 (2022).
378 379	28.	Carmona-Pírez, J. <i>et al.</i> Multimorbidity clusters in patients with chronic obstructive airway diseases in the EpiChron Cohort. <i>Sci Rep</i> 11 , 4784 (2021).
380 381 382	29.	Launders, N., Hayes, J. F., Price, G. & Osborn, D. P. Clustering of physical health multimorbidity in people with severe mental illness: An accumulated prevalence analysis of United Kingdom primary care data. <i>PLoS Med</i> 19 , e1003976 (2022).
383 384	30.	Guisado-Clavero, M. <i>et al.</i> Multimorbidity patterns in the elderly: a prospective cohort study with cluster analysis. <i>BMC Geriatr</i> 18 , 16 (2018).
385 386	31.	Sinaga, K. P. & Yang, MS. Unsupervised K-means clustering algorithm. <i>IEEE access</i> 8 , 80716–80727 (2020).
387 388	32.	Sudlow, C. <i>et al.</i> UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. <i>PLoS Med</i> 12 , e1001779 (2015).

- 389 33. Ho, I. S. S. *et al.* Measuring multimorbidity in research: Delphi consensus study. *BMJ Medicine* 1, e000247 (2022).
- 391 34. Prigge, R. *et al.* Robustly Measuring Multiple Long-Term Health Conditions Using Disparate
 392 Linked Datasets in UK Biobank. *Preprints with The Lancet* (2024).
- 393 35. Huang, Z. Clustering large data sets with mixed numeric and categorical values. in *Proceedings of* 394 *the 1st pacific-asia conference on knowledge discovery and data mining*, (PAKDD) 21–34 (1997).
- 395 36. Cao, F., Liang, J. & Bai, L. A new initialization method for categorical data clustering. *Expert Syst* 396 *Appl* 36, 10223–10228 (2009).
- 397 37. Abad-D\'\iez, J. M. *et al.* Age and gender differences in the prevalence and patterns of
 398 multimorbidity in the older population. *BMC Geriatr* 14, 1–8 (2014).
- 399 38. Agur, K., McLean, G., Hunt, K., Guthrie, B. & Mercer, S. W. How does sex influence
 400 multimorbidity? Secondary analysis of a large nationally representative dataset. *Int J Environ Res*401 *Public Health* 13, 391 (2016).
- 402 39. Robert, L. Thorndike."Who Belongs in the Family?". *Psychometrika* 18, 267–276 (1953).
- 403 40. Schwarz, G. Estimating the dimension of a model. *The annals of statistics* 461–464 (1978).
- 404 41. Hamming, R. W. Entropy and Shannon's First Theorem. *Coding and information*405 *theory.(Prentice-Hall Inc. Englewood Cliffs, New Jersey)* 107, (1980).
- 406 42. Caliński, T. & Harabasz, J. A dendrite method for cluster analysis. *Communications in Statistics-*407 *theory and Methods* 3, 1–27 (1974).
- 408 43. Davies, D. L. & Bouldin, D. W. A cluster separation measure. *IEEE Trans Pattern Anal Mach*409 *Intell* 2, 224–227 (1979).
- 410 44. Rousseeuw, P. J. Silhouettes: A graphical aid to the interpretation and validation of cluster
 411 analysis. J Comput Appl Math 20, 53–65 (1987).
- 412 45. Huang, Z. A fast clustering algorithm to cluster very large categorical data sets in data mining.
 413 Data Min Knowl Discov 3, 34–39 (1997).
- 414 46. Dunn, O. J. Multiple comparisons among means. J Am Stat Assoc 56, 52–64 (1961).
- 415 47. Bland, J. M. & Altman, D. G. Multiple significance tests: the Bonferroni method. *Bmj* 310, 170 (1995).
- 417 48. Guide, P. Fisher's Exact Test. Preprint at
 418 https://www.pathwaycommons.org/guide/primers/statistics/fishers_exact_test/.
- 419 49. Cox, D. R. Regression models and life-tables. *Journal of the Royal Statistical Society: Series B*420 (*Methodological*) 34, 187–202 (1972).
- 421 50. Satagopan, J. M. *et al.* A note on competing risks in survival data analysis. *Br J Cancer* 91, 1229–1235 (2004).
- 423 51. Khunti, K., Routen, A., Banerjee, A. & Pareek, M. The need for improved collection and coding
 424 of ethnicity in health research. *J Public Health (Bangkok)* 43, e270–e272 (2021).

425	52.	Townsend, P. Deprivation. J Soc Policy 16, 125–146 (1987).	
-			

- 426 53. Restocchi, V., Villegas, J. G. & Fleuriot, J. D. Multimorbidity profiles and stochastic block
 427 modeling improve ICU patient clustering. in 2022 22nd IEEE International Symposium on
 428 Cluster, Cloud and Internet Computing (CCGrid) 925–932 (IEEE, 2022).
 429 doi:10.1109/CCGrid54584.2022.00112.
- 430 54. MacQueen, J. Classification and analysis of multivariate observations. in *5th Berkeley Symp.*431 *Math. Statist. Probability* 281–297 (1967).
- 432 55. Abdi, H. & Dominique Valentin. Multiple correspondence analysis. *Encyclopedia of measurement and statistics* 2, 651–657 (2007).
- 434 56. Beaney, T. *et al.* Identifying multi-resolution clusters of diseases in ten million patients with
 435 multimorbidity in primary care in England. *Communications Medicine* 4, 102 (2024).
- 436 57. Ho, I. S. S. *et al.* Measuring multimorbidity in research: Delphi consensus study. *BMJ Medicine* 1, e000247 (2022).
- 438 58. Fry, A. *et al.* Comparison of Sociodemographic and Health-Related Characteristics of UK
 439 Biobank Participants With Those of the General Population. *Am J Epidemiol* 186, 1026–1034
 440 (2017).

1

2 Supplementary Table 1. 69 physical conditions with corresponding bodily systems.

System	Condition
Skin conditions	Psoriasis
Perinatal conditions	Down's syndrome
	Migraine
	Peripheral or autonomic neuropathy
	Epilepsy
	Cerebral Palsy
	Motor neuron disease
	Multiple sclerosis
	Myasthenia gravis
	Parkinson's disease
Neurological conditions	Postviral fatigue syndrome, neurasthenia and fibromyalgia
	Inflammatory arthritis and other inflammatory conditions
	Gout
	Osteoporosis and vertebral crush fractures
	Osteoarthritis (excl spine)
Musculoskeletal conditions	Spinal stenosis
Mental Health Disorders	Dementia
Infectious Diseases	Tuberculosis
Infectious Diseases	HIV
	Sarcoidosis
	Iron and vitamin deficiency anaemia
	Immunodeficiencies
Haematological/Immunological	Sickle-cell anaemia
conditions	Thalassaemia
	Sleep apnoea
	COPD
	Bronchiectasis
	Asthma
	Asbestosis
Diseases of the Respiratory System	Allergic and chronic rhinitis
	Chronic renal disease
	Urinary Incontinence
	Erectile dysfunction
	Non-acute cystitis
Diseases of the Genitourinary system	Hyperplasia of prostate
	Visual impairment and blindness
	Macular degeneration
Diseases of the Eye	Glaucoma
	Hypo or hyperthyroidism
	Addisons disease
	Cystic Fibrosis
Diseases of the Endocrine System	Diabetes NOS

	Type 1 diabetes
	Type 2 diabetes
	Meniere disease
Diseases of the Ear	Hearing loss
	Fatty Liver
	Chronic liver disease
	Peptic ulcer disease
	Irritable bowel syndrome
	Diverticular disease of intestine (acute and chronic)
	Gastro-oesophageal reflux, gastritis and similar
	Coeliac disease
Diseases of the Digestive System	Inflammatory bowel disease
	Conduction disorders and other arrhythmias
	Coronary heart disease
	Cardiomyopathy
	Heart valve disorders
	Atrial fibrillation
	Transient ischaemic attack
	Peripheral arterial disease
	Hypertension
	Heart failure
	Primary pulmonary hypertension
Diseases of the Circulatory System	Stroke
	Solid organ malignancies
	Haematological malignancies
Cancers	Non-melanoma skin malignancies
	Benign neoplasm of brain and other parts of central nervous
Benign Neoplasm/CIN	system

•

- 12
- 13



1. Excluding participants who withdrew permission for their data to be included in research before 13 October 2023

14

15

medRxiv preprint doi: https://doi.org/10.1101/2024.07.05.24310004; this version posted July 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Supplementary Appendix 1. Methodological Descriptions.

17

58

59

To identify a clustering method best suited for our data, we explored several combinations of 18 19 metrics and methods which were, in theory, capable of handling the binary nature of the morbidity 20 data. Specifically, we used the following metrics within this study:

Hamming distance ¹: This is a dissimilarity metric denoting the number of mismatching 21 categories between two objects. It is formally defined as ²: 22 $d_{hamming}(X,Y) = \sum_{i=1}^{m} \delta(x_i, y_i),$ 23 24 where: $\delta(x_j, y_j) = \begin{cases} 0 & if \ x_j = y_j \\ 1 & if \ x_j \neq y_j \end{cases}$ 25 cosine similarity ³: This is a measure which was originally used to indicate how similar two 26 27 vector angles are to one another. For binary data, it can be understood as the number of true, or positive features are shared between two objects, divided by the product of the number of 28 true objects from each object. Formally, it is defined as ⁴: 29 $s_{cosine}(X,Y) = \frac{X \cdot Y}{\|X\| \cdot \|Y\|}$ 30 31 With these metrics, we explored the following four clustering methods: 32 *k*-modes ^{5,6}: This uses the same methodology as *k*-means clustering ⁷, but the centroid of each 33 cluster is defined on the number of matching categories between data points, computed via 34 the Hamming distance ¹. In other words, the centroid represents the mode of the cluster, rather 35 than the mean ^{5,6}. Centroid initialization was performed via the frequency-based *Huang* 36 metric ⁵. 37 *k*-medoids ⁸: As above, this uses the same methodology as *k*-means clustering ⁷, but the • 38 centroid is an actual data point acting as the "median", computed via cosine similarity. 39 Latent Class Analysis (LCA) ⁹: This aims to find groups or subtypes of cases (latent classes) 40 • in multivariate categorical data. It gives probabilities of class membership, rather than 41 42 concrete class assignments, which are unique, so the user can see the likelihood that a data point truly belongs to its assigned class ⁹. 43 agglomerative hierarchical clustering (AHC) ¹⁰: This is best understood as a "bottom-up" 44 • approach in which samples start out alone, then merge to form larger and larger clusters ¹¹. 45 We used a *complete* linkage (the maximum distance between points in two clusters ¹²), 46 computed via Hamming distance¹. 47 48 Finally, we assessed cluster performance, including separation and overlap, with the following three 49 50 performance metrics: Calinski and Harabasz score¹³: This is the ratio of between-cluster dispersion to within-51 • cluster dispersion. A higher Calinski and Harabasz score indicates better performance. 52 **Davies Bouldin score**¹⁴: This is a measure of cluster similarity to each cluster's most similar 53 • cluster. A Davies Bouldin score closer to zero indicates better performance. 54 Silhouette score ¹⁵: This is a measure of cluster fit which accounts for the mean distance 55 • 56 between points in each individual cluster as well as the mean distance to points in the closest neighboring cluster. A silhouette score closer to one indicates better performance. Hamming 57

distance was utilized as the distance metric.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.05.24310004; this version posted July 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license... The best similarity or dissimilarity metrics were selected for *k*-modes, *k*-medoids, and AHC by testing 60 each of them upon a random selection of participants (1,417). The k-modes method used with an 61 alternative initialization technique, called the *Cao* metric ⁶, resulted in some clusters containing less 62 than ten participants, while others contained hundreds. Such imbalance is uninformative for our 63 purposes. Similarly, k-medoids with Hamming distance and Jaccard similarity ¹⁶, another similarity 64 65 metric, resulted in several empty clusters. Finally, AHC with other metrics and linkage types resulted in poor separation between clusters, with high overlap between branches. These issues were not 66 present with the specified metrics. 67

68

70

The *bubble heatmap* places ARF values on a grid in which the *y*-axis contains conditions, the *x*-axis 71

72 contains clusters, and data points are colored blue (under-representation) or red (over-representation)

at each intersection. The magnitude of under- or over-representation is indicated by the size of the 73

74 data point, or *bubble*. Points are not statistically significant, as determined by the Fisher's Exact test

75 (REF), were omitted. Therefore, conditions with no significant values are omitted entirely from the y-76 axis.

Notably, for visualisation purposes, the ARF values are adjusted so that values denoting under-77

representation (between zero and one) were mapped to a similar scale as those denoting over-78

79 representation (values greater than one). Specifically, we used the following function, in which x

80 denotes the original ARF value:

81
$$f(x) = \frac{2(x-1)}{(x+1)}$$

82

medRxiv preprint doi: https://doi.org/10.1101/2024.07.05.24310004; this version posted July 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. Supplementary Table 2. ARF values and adjusted p-values per condition and cluster.

- Statistically significant values (p < 0.05) are denoted in bold.
- See corresponding excel file (S2Table.xlsx).

Cluster Label	Num. conditions significantly over- represented	Num. conditions significantly under- represented	Explanation
		-	
Very extensive morbidity	41	4	represented with no stand-out conditions or groups.
Migraine	7	21	Migraine has large over-representation with relatively small over- representation of six other conditions.
Pagniratory	Q	10	Four respiratory conditions have large over-representation, with four other conditions significantly over-
Respiratory	δ	19	Three respiratory conditions are
Respiratory w/o other	3	29	significantly over-represented, with widespread significant under- representation of other conditions.
CVD + diabetes	16	27	Nine cardiovascular disease (CVD) conditions and three diabetes types are significantly over-represented but, unlike 'very extensive morbidity', many other conditions are under- represented.
Mixed including cancer	23	21	Twenty-three conditions, including cancers, are significantly over- represented with no stand-out conditions or groups, but CVD and respiratory conditions are significantly under-represented. However, over- represented conditions are relatively rare so this group is relatively healthy.
Haalthaa Labiaitia	1	41	Allergic and chronic rhinitis is significantly over-represented, with significant under-representation of 41
Healthy + rhinitis	1	41	Other conditions
Macular degeneration + diabetes	5	6	significantly over-represented, of which macular degeneration has the highest prevalence.

	No. of conditions significantly over-	No. of conditions significantly under-	E
Cluster Label	represented	represented	Explanation
Very extensive morbidity	34	0	34 conditions are significantly over- represented with no stand-out conditions or groups.
Extensive morbidity	23	2	23 conditions are significantly over- represented with no stand-out conditions or groups and two relatively small under-representation of two conditions.
Respiratory	4	14	Four respiratory conditions have large over-representation, with no other significantly over-represented conditions.
Digestive	5	3	Four digestive conditions are significantly over-represented, two of which are largely over-represented. Additionally, one CVD condition is over-represented, but the other 11 CVD conditions are not.
MSK	7	11	Five musculoskeletal (MSK) conditions are significantly over-represented, with relatively small over-representation of two other conditions and under- representation of 11 other conditions.
CVD + diabetes	15	18	Nine CVD conditions and three diabetes types are significantly over- represented, but, unlike 'very extensive morbidity', many other conditions are under-represented.
Mixed including cancer	17	18	Seventeen conditions, including cancers, are significantly over- represented with no stand-out conditions or groups, but CVD, respiratory and MSK are significantly under-represented. However, over- represented conditions are relatively rare, so this group is relatively healthy.
Healthy + rhinitis	1	44	Allergic and chronic rhinitis is significantly over-represented, with significant under-representation of 44 other conditions.

	No. of conditions significantly over-	No. of conditions significantly under-	Fordersetter
Very extensive morbidity	29	3	29 conditions are significantly over- represented with no stand-out conditions or groups. While three conditions have relatively small under-representation, there are no stand- out conditions or groups amongst them either.
MSK + others	14	7	Four musculoskeletal conditions are significantly over represented, but additionally 10 other conditions with no stand out pattern (unlike the Women-only <i>MSK</i> cluster, which is more purely MSK).
Respiratory + gout + male genitourinary	6	1	Three respiratory conditions, gout, and two genitourinary conditions affecting primarily men have large over-representation, while only one condition has relatively small under- representation.
Digestive	6	6	Four digestive conditions have large over- representation, with two other conditions significantly over-represented.
CVD + diabatas	11	20	Eight CVD conditions and two diabetes types are significantly over-represented, in addition to one other condition, but, unlike 'very extensive morbidity', many other conditions
CVD + CKD + gout	11	5	Seven CVD conditions are significantly over- represented. Additionally, gout and chronic renal/kidney disease (CKD) have large over- representation.
Mixed including cancer	19	18	Nineteen conditions, including cancers, are significantly over-represented with no stand- out conditions or groups, but CVD, respiratory and MSK are significantly under-represented. However, the over-represented conditions are relatively rare, so this group is relatively healthy.
Healthy + rhinitis	2	42	Allergic and chronic rhinitis as well as Asthma are significantly over-represented, with significant under-representation of 42 other conditions



Corresponds to Fig. 1. Conditions with a prevalence of zero are omitted.



104 Supplementary Figure 3. Time-to-depression diagnosis for each cluster in each of the *k*-modes models.

106 All *y*-axes are cropped for better resolution between curves.

	Very					Mixed		Macular
	extensive			Respiratory	CVD +	including	Healthy +	degeneration
Condition	morbidity	Migraine	Respiratory	w/o other	diabetes	cancer	rhinitis	+ diabetes
Addisons disease	0.64	1.20	1.62	1.85	1.17	0.81	0.87	0.00
Allergic and chronic								
rhinitis	0.20	0.78	2.97	0.00	0.00	0.00	2.97	0.00
Asbestosis	2.23	0.43	0.56	0.86	0.95	1.15	0.57	0.77
Asthma	0.86	0.44	6.05	6.05	0.53	0.00	0.00	0.58
Atrial fibrillation	1.78	0.73	0.78	0.56	1.48	0.84	0.70	1.22
Benign neoplasm of								
brain and other								
parts of central								
nervous system	1.21	1.06	0.84	0.76	0.87	1.22	0.80	0.42
Bronchiectasis	1.31	0.48	2.29	2.72	0.71	0.85	0.58	1.37
COPD	1.88	0.55	2.43	3.41	0.87	0.55	0.32	0.95
Cardiomyopathy	1.65	0.51	0.91	0.64	1.57	0.82	0.74	1.35
Cerebral Palsy	1.16	0.54	0.70	0.46	1.10	1.34	0.80	0.96
Chronic liver								
disease	1.57	0.75	0.90	1.05	0.72	1.20	0.76	0.63
Chronic renal								
disease	2.09	0.74	0.73	0.39	1.55	0.74	0.64	1.19
Coeliac disease	0.93	1.01	1.30	0.90	0.48	1.30	0.93	0.92
Conduction								
disorders and other								
arrhythmias	1.38	1.09	0.95	0.71	1.10	1.08	0.65	1.29
Coronary heart								
disease	2.26	0.69	0.75	0.52	1.58	0.67	0.60	1.13
Cystic Fibrosis	0.99	0.84	0.98	0.72	0.67	1.26	1.02	1.50
Dementia	1.39	0.60	1.09	0.71	1.05	1.32	0.55	0.00
Diabetes NOS	1.78	0.78	0.76	0.78	1.71	0.72	0.60	1.91
Diverticular disease								
of intestine (acute								
and chronic)	1.86	0.93	0.93	0.78	0.81	0.98	0.77	1.15
Down's syndrome	0.67	0.49	0.00	1.93	0.27	2.09	0.56	6.07
Epilepsy	0.93	1.09	0.95	0.78	0.76	1.37	0.77	0.89

Supplementary Table 2.a. ARF values for *whole*-cohort clusters.

Erectile dysfunction	1.67	0.54	0.70	0.59	1.24	1.04	0.77	1.47
Fatty Liver	2.15	0.87	1.40	0.58	1.09	0.59	0.82	0.17
Gastro-								
oesophageal reflux,								
gastritis and similar	3.23	0.96	0.96	0.64	0.00	0.86	0.74	0.41
Glaucoma	1.25	0.79	0.80	0.66	1.16	1.13	0.75	2.97
Gout	1.94	0.48	0.72	0.53	1.50	0.87	0.68	1.02
HIV	0.61	0.85	1.16	0.56	0.60	1.45	1.00	1.18
Haematological								
malignancies	1.17	0.77	0.79	0.72	1.02	1.32	0.72	0.77
Hearing loss	1.50	0.82	0.86	0.80	0.94	1.15	0.74	1.01
Heart failure	2.34	0.56	0.79	0.48	1.74	0.60	0.56	1.50
Heart valve								
disorders	1.51	1.06	0.79	0.52	1.28	0.96	0.71	1.25
Hyperplasia of								
prostate	1.54	0.56	0.74	0.69	1.05	1.15	0.80	1.16
Hypertension	2.32	0.76	0.77	0.00	2.72	0.00	0.69	0.90
Hypo or								
hyperthyroidism	1.11	1.01	0.96	0.83	0.83	1.22	0.82	1.07
Immunodeficiencies	1.39	1.16	0.98	0.77	0.64	1.13	0.82	2.41
Inflammatory								
arthritis and other								
inflammatory								
conditions	1.69	1.00	0.90	0.69	0.71	1.11	0.79	0.74
Inflammatory bowel								
disease	1.05	0.87	0.98	0.88	0.68	1.31	0.89	0.60
Iron and vitamin								
deficiency anaemia	1.26	1.22	0.94	0.76	0.67	1.22	0.79	0.89
Irritable bowel								
syndrome	1.15	1.45	1.17	0.88	0.44	1.10	0.97	0.62
Macular								
degeneration	1.33	0.86	0.85	0.00	0.00	0.00	0.80	74.74
Meniere disease	1.40	1.29	0.83	0.73	0.71	1.11	0.85	0.94
Migraine	0.29	10.17	1.12	0.00	0.00	0.00	0.00	0.00
Motor neuron								
disease	1.51	1.26	0.32	0.63	0.35	1.45	0.85	0.00
Multiple sclerosis	0.57	1.12	0.81	0.76	0.71	1.59	0.77	1.20
Myasthenia gravis	1.40	0.88	1.19	1.45	0.48	1.12	0.85	1.82

Non-acute cystitis	1.41	1.50	0.69	0.89	0.89	1.03	0.77	0.47
Non-melanoma								
skin malignancies	1.09	0.81	0.79	0.75	0.89	1.36	0.78	1.04
Osteoarthritis (excl								
spine)	3.05	0.92	0.83	0.66	0.00	0.98	0.74	0.50
Osteoporosis and								
vertebral crush								
fractures	1.32	1.01	1.05	0.84	0.62	1.25	0.78	1.20
Parkinson's								
disease	1.27	0.45	0.83	0.96	0.94	1.39	0.69	0.93
Peptic ulcer								
disease	2.20	0.89	0.71	0.72	0.62	1.09	0.69	0.82
Peripheral arterial								
disease	2.31	0.61	0.68	0.57	1.56	0.73	0.55	1.28
Peripheral or								
autonomic								
neuropathy	1.88	1.01	0.91	0.80	0.95	0.88	0.74	1.59
Postviral fatigue								
syndrome,								
neurasthenia and								
fibromyalgia	1.26	1.45	1.35	0.90	0.48	0.99	0.96	0.66
Primary pulmonary								
hypertension	2.00	1.20	0.95	0.26	1.76	0.69	0.31	3.31
Psoriasis	1.05	0.85	0.85	0.77	0.80	1.25	0.96	0.84
Sarcoidosis	1.07	0.64	1.21	1.27	0.88	1.20	0.80	0.71
Sickle-cell anaemia	0.90	1.54	0.90	0.88	0.73	1.42	0.60	0.00
Sleep apnoea	1.74	0.76	1.12	0.61	1.12	0.76	0.93	0.74
Solid organ								
malignancies	1.14	0.89	0.81	0.85	0.86	1.32	0.76	1.09
Spinal stenosis	2.04	0.76	0.97	0.49	0.70	1.10	0.71	0.69
Stroke	1.97	1.25	0.72	0.43	1.65	0.66	0.53	1.33
Thalassaemia	0.92	0.84	0.86	1.34	0.98	1.16	0.94	0.00
Transient								
ischaemic attack	2.18	1.27	0.69	0.36	1.43	0.72	0.54	0.85
Tuberculosis	1.39	0.80	0.99	0.86	0.80	1.21	0.76	1.35
Type 1 diabetes	1.25	0.51	0.82	0.55	1.59	0.97	0.72	4.52
Type 2 diabetes	2.18	0.49	0.84	0.42	1.87	0.54	0.64	1.61

Incontinence 1.31 1.37 1.21 0.88 0.53 1.10 0.84 0.80								
Visual impairment	ntinence 1.31	1.37	1.21	0.88	0.53	1.10	0.84	0.80
and blindness 150 125 109 035 066 079 078 1517	al impairment	1 25	1 09	0.35	0.66	0.79	0.78	15 17

Verv Mixed CVD + extensive including Healthy + Extensive MSK Condition morbiditv morbidity Respiratory Digestive diabetes cancer rhinitis Addisons disease 1.28 1.20 1.15 0.00 0.56 0.74 1.43 0.80 Allergic and chronic rhinitis 2.37 0.44 2.80 0.68 0.44 0.53 0.00 2.80 Asbestosis 0.00 2.18 0.98 0.90 0.00 0.00 0.00 0.87 Asthma 0.74 5.79 0.58 0.54 0.47 0.78 0.00 1.67 1.91 1.42 0.63 1.54 1.25 1.50 0.76 0.29 Atrial fibrillation Benign neoplasm of brain and other parts of central 1.27 1.07 nervous system 0.84 0.83 0.94 1.02 1.17 0.63 1.61 1.20 2.29 0.56 1.01 0.74 0.96 0.49 **Bronchiectasis** COPD 2.03 1.81 2.26 2.08 1.01 0.86 0.83 0.20 1.09 0.62 2.06 1.37 1.08 1.79 0.75 0.34 Cardiomyopathy Cerebral Palsy 0.94 1.96 0.00 2.47 1.09 0.91 1.40 0.45 Chronic liver 1.37 1.58 0.91 0.92 0.76 0.68 1.05 1.24 disease Chronic renal 1.96 1.08 disease 1.67 1.77 0.65 1.63 0.70 0.36 1.19 1.32 1.17 2.56 0.70 0.60 1.25 1.04 Coeliac disease Conduction disorders and other 0.89 1.40 1.44 0.79 1.58 1.17 1.08 0.56 arrhythmias Coronary heart disease 2.21 2.04 0.68 1.88 1.10 1.66 0.57 0.25 0.79 0.72 1.29 1.26 Cystic Fibrosis 0.41 1.03 0.90 1.63 1.29 Dementia 1.07 0.62 0.00 1.19 0.99 1.33 0.31 **Diabetes NOS** 1.83 1.50 0.62 2.25 1.00 1.57 0.78 0.39 Diverticular disease of intestine (acute 0.84 and chronic) 2.24 2.14 1.10 0.86 0.51 1.73 0.94 0.32 0.27 2.69 0.00 0.00 0.00 0.00 0.66 Down's syndrome 1.04 0.98 Epilepsy 1.16 0.48 0.92 0.77 1.33 0.73

Supplementary Table 2.b. ARF values for women-only clusters.

Erectile dysfunction								
Fatty Liver	3.31	3.14	0.98	1.84	0.76	1.31	0.48	0.35
Gastro-								
oesophageal reflux,								
gastritis and similar	1.87	5.43	1.00	5.43	0.00	0.81	0.93	0.61
Glaucoma	1.24	1.39	0.67	0.52	1.07	1.19	1.02	0.64
Gout	1.86	1.85	0.96	2.51	1.34	1.43	0.57	0.31
HIV	0.31	0.59	1.02	0.00	0.05	0.68	1.83	1.24
Haematological								
malignancies	0.91	1.06	0.90	0.95	0.98	1.06	1.27	0.51
Hearing loss	1.66	1.46	0.90	0.90	1.15	0.87	1.03	0.64
Heart failure	2.19	1.56	1.03	1.76	1.20	1.65	0.56	0.16
Heart valve								
disorders	1.58	1.27	0.63	1.18	0.95	1.28	1.03	0.53
Hyperplasia of								
prostate								
Hypertension	2.57	1.06	0.60	1.13	0.87	3.09	0.00	0.00
Hypo or								
hyperthyroidism	1.18	1.14	0.84	0.95	0.94	1.01	1.17	0.70
Immunodeficiencies	1.81	0.97	0.93	4.07	0.36	1.12	1.36	0.46
Inflammatory								
arthritis and other								
inflammatory								
conditions	1.79	1.93	0.77	1.23	1.37	0.79	0.91	0.59
Inflammatory bowel								
disease	1.21	1.22	0.84	0.98	0.89	0.74	1.29	0.84
Iron and vitamin								
deficiency anaemia	1.14	1.30	0.92	1.47	0.79	0.84	1.28	0.79
Irritable bowel								
syndrome	4.46	0.85	0.69	1.39	0.47	0.49	1.11	0.90
Macular		4.00	o -				4.00	
degeneration	1.72	1.26	0.75	0.80	1.05	1.16	1.00	0.54
Meniere disease	2.20	1.90	0.78	1.58	0.96	0.81	0.98	0.71
Migraine	1.42	1.13	0.98	1.31	0.85	0.76	1.22	0.85
Motor neuron								
disease	3.20	1.99	0.00	0.00	1.11	0.46	1.24	0.57
Multiple sclerosis	0.95	0.53	0.73	1.29	0.67	0.74	1.61	0.82

Myasthenia gravis	2.20	0.91	0.79	0.00	1.15	0.53	1.14	0.92
Non-acute cystitis	1.70	2.02	0.66	2.78	0.88	0.98	0.97	0.73
Non-melanoma								
skin malignancies	0.97	1.07	0.77	1.07	1.07	0.85	1.28	0.69
Osteoarthritis (excl								
spine)	3.19	3.71	0.55	0.00	3.71	0.00	0.00	0.00
Osteoporosis and								
vertebral crush								
fractures	1.39	1.53	0.90	1.27	1.20	0.77	1.09	0.64
Parkinson's								
disease	1.47	1.64	0.85	2.31	1.27	0.89	1.00	0.53
Peptic ulcer								
disease	1.71	3.43	0.80	35.75	0.69	0.43	0.61	0.30
Peripheral arterial								
disease	2.05	2.07	0.62	2.26	1.01	1.37	0.79	0.37
Peripheral or								
autonomic								
neuropathy	2.00	1.91	0.93	2.03	1.22	0.87	0.89	0.51
Postviral fatigue								
syndrome,								
neurasthenia and								
fibromyalgia	2.35	1.84	1.13	1.30	0.90	0.61	0.96	0.85
Primary pulmonary								
hypertension	0.00	2.53	0.73	2.66	0.82	1.96	0.98	0.00
Psoriasis	1.16	1.18	0.86	1.34	1.01	0.77	1.21	0.83
Sarcoidosis	0.99	1.71	1.15	1.30	0.99	1.05	1.02	0.61
Sickle-cell anaemia	0.95	0.00	1.37	0.00	1.16	0.83	1.38	0.51
Sleep apnoea	2.98	1.52	1.27	2.31	0.83	1.23	0.62	0.54
Solid organ								
malignancies	1.02	1.16	0.76	1.17	0.95	0.92	1.27	0.71
Spinal stenosis	2.51	2.40	0.91	1.06	1.94	0.56	0.63	0.37
Stroke	1.94	1.64	0.71	1.86	1.07	1.63	0.70	0.28
Thalassaemia	0.57	1.91	0.83	0.00	0.66	0.89	1.26	1.03
Transient								
ischaemic attack	2.17	2.21	0.53	1.33	1.11	1.53	0.67	0.29
Tuberculosis	1.52	1.46	0.82	0.88	1.22	0.87	1.01	0.71
Type 1 diabetes	1.15	1.01	0.83	2.13	0.71	1.57	0.98	0.61
Type 2 diabetes	2.33	1.58	0.79	1.24	1.09	1.90	0.47	0.22

Lirinan/								
Incontinence	1.81	1.57	0.98	1.11	1.03	0.76	1.05	0.73
Visual impairment								
and blindness	2.37	1.53	0.89	0.74	1.05	0.98	0.92	0.54

Supplementar	y Table 2.c.	ARF values for	men-only clusters.
--------------	--------------	----------------	--------------------

	Very		Respiratory +				Mixed	
	extensive		gout + male		CVD +	CVD + CKD +	including	Healthy +
Condition	morbidity	MSK + others	genitourinary	Digestive	diabetes	gout	cancer	rhinitis
Addisons disease	1.29	0.48	0.00	0.00	1.13	0.64	0.73	1.93
Allergic and chronic								
rhinitis	0.49	0.80	2.78	0.71	0.74	0.38	0.00	3.20
Asbestosis	1.17	1.66	0.54	1.85	0.75	0.58	1.05	0.44
Asthma	0.72	0.86	6.08	0.76	0.82	0.39	1.02	1.46
Atrial fibrillation	1.54	1.01	1.37	1.05	1.18	1.81	0.80	0.43
Benign neoplasm of								
brain and other								
parts of central								
nervous system	1.50	1.10	1.16	0.55	0.89	0.91	1.15	0.70
Bronchiectasis	1.04	1.16	2.20	0.55	0.83	0.94	1.23	0.81
COPD	1.30	1.44	2.82	1.48	0.91	0.96	0.85	0.46
Cardiomyopathy	1.61	0.89	2.60	1.02	1.14	2.15	0.68	0.55
Cerebral Palsy	0.44	1.14	2.06	0.88	1.12	1.10	1.40	0.42
Chronic liver								
disease	1.35	0.84	1.74	2.12	0.82	1.32	1.20	0.63
Chronic renal								
disease	1.95	0.90	1.23	1.03	1.22	2.57	0.64	0.26
Coeliac disease	0.91	0.79	2.29	0.93	0.75	0.84	1.53	0.98
Conduction								
disorders and other								
arrhythmias	1.24	0.90	0.91	1.14	1.14	1.36	1.13	0.50
Coronary heart								
disease	1.70	1.10	1.08	1.07	1.33	1.49	0.69	0.26
Cystic Fibrosis	0.00	0.44	0.00	2.35	1.03	5.28	0.40	1.45
Dementia	1.68	1.47	1.74	1.48	0.87	1.48	0.51	0.61
Diabetes NOS	2.61	0.84	1.30	0.74	1.38	1.06	0.66	0.20
Diverticular disease								
of intestine (acute								
and chronic)	1.26	1.29	1.64	1.30	0.89	1.29	0.99	0.52
Down's syndrome	0.00	1.05	0.00	0.00	0.00	0.00	2.89	1.16
Epilepsy	0.99	1.02	0.69	0.79	0.82	0.78	1.55	0.69

Erectile dysfunction	8.11	0.57	4.30	0.44	0.00	0.00	0.00	0.41
Fatty Liver	1.64	1.03	1.06	1.09	1.19	1.36	0.69	0.61
Gastro-								
oesophageal reflux,								
gastritis and similar	1.14	1.15	1.10	2.31	0.77	0.94	1.14	0.65
Glaucoma	1.24	0.97	1.05	0.85	1.08	1.03	1.20	0.57
Gout	1.36	0.48	8.30	0.32	0.00	13.49	0.00	0.27
HIV	1.11	0.66	1.47	1.04	0.77	0.31	1.78	0.86
Haematological								
malignancies	1.12	0.93	0.67	1.36	0.89	1.48	1.28	0.64
Hearing loss	1.31	1.29	1.37	1.06	0.85	0.90	1.17	0.51
Heart failure	1.82	1.03	1.40	1.22	1.29	2.29	0.55	0.24
Heart valve								
disorders	1.38	1.03	1.39	1.25	1.16	1.37	0.90	0.48
Hyperplasia of								
prostate	1.46	1.24	1.42	0.86	0.85	0.84	1.12	0.60
Hypertension	1.57	0.86	0.60	0.80	2.37	1.70	0.00	0.00
Hypo or								
hyperthyroidism	1.24	0.94	1.55	0.82	1.01	0.82	1.24	0.68
Immunodeficiencies	1.61	1.38	0.00	0.00	0.78	0.80	1.18	0.66
Inflammatory								
arthritis and other								
inflammatory								
conditions	1.02	1.62	1.33	1.04	0.75	1.31	1.02	0.51
Inflammatory bowel								
disease	1.03	0.93	0.94	1.28	0.76	0.76	1.37	0.96
Iron and vitamin								
deficiency anaemia	1.30	1.09	1.40	1.83	0.79	1.08	1.14	0.63
Irritable bowel								
syndrome	0.96	1.01	1.10	1.43	0.74	0.68	1.33	0.98
Macular								
degeneration	1.44	1.01	1.38	1.02	0.99	0.91	1.17	0.56
Meniere disease	1.02	1.22	1.54	1.39	0.87	0.82	1.31	0.48
Migraine	0.95	0.99	0.89	0.96	0.84	0.68	1.40	0.90
Motor neuron								
disease	1.23	1.81	0.00	0.00	0.48	0.81	0.93	1.12
Multiple sclerosis	2.32	0.43	1.03	1.17	0.73	0.44	1.52	0.78
Myasthenia gravis	1.67	1.31	0.00	0.88	0.90	0.00	1.05	0.73

Non-acute cystitis	1.52	1.08	1.57	0.45	0.98	0.67	1.38	0.37
Non-melanoma								
skin malignancies	1.02	1.08	0.98	0.76	0.88	1.03	1.36	0.67
Osteoarthritis (excl								
spine)	0.95	4.45	1.19	0.00	0.00	1.01	0.00	0.00
Osteoporosis and								
vertebral crush								
fractures	1.34	1.29	1.38	0.98	0.76	0.76	1.18	0.65
Parkinson's								
disease	2.08	0.88	1.52	1.01	0.70	0.76	1.43	0.48
Peptic ulcer								
disease	0.82	1.18	0.74	18.36	0.00	0.80	0.00	0.00
Peripheral arterial								
disease	2.29	1.14	0.47	1.32	1.20	1.33	0.61	0.20
Peripheral or								
autonomic								
neuropathy	2.02	1.30	0.99	1.36	0.87	1.16	0.78	0.44
Postviral fatigue								
syndrome,								
neurasthenia and								
fibromyalgia	1.20	1.05	0.99	1.12	0.64	0.77	1.26	1.07
Primary pulmonary								
hypertension	1.48	0.87	0.00	0.78	1.84	1.17	0.67	0.16
Psoriasis	1.08	0.94	1.03	0.84	0.82	1.01	1.34	0.89
Sarcoidosis	0.82	0.80	2.32	0.56	0.89	0.99	1.66	0.70
Sickle-cell anaemia	0.00	1.31	0.00	1.76	1.03	0.00	1.20	1.09
Sleep apnoea	1.62	1.21	0.95	0.95	1.02	1.34	0.80	0.57
Solid organ								
malignancies	1.62	1.00	1.27	1.07	0.83	0.99	1.25	0.57
Spinal stenosis	1.11	2.01	1.53	0.62	0.68	1.21	0.84	0.46
Stroke	1.73	1.02	0.61	1.07	1.44	1.67	0.64	0.23
Thalassaemia	0.91	0.78	0.00	1.80	0.70	1.80	1.33	0.99
Transient								
ischaemic attack	1.78	1.13	0.80	0.92	1.30	1.72	0.70	0.20
Tuberculosis	0.98	1.01	1.89	1.07	0.84	1.13	1.47	0.56
Type 1 diabetes	2.92	0.53	1.72	0.59	1.23	0.22	0.99	0.42
Type 2 diabetes	2.56	0.91	1.10	0.84	1.37	1.57	0.49	0.22

Urinary								
Incontinence	2.20	1.24	1.55	0.79	0.63	0.48	1.03	0.71
Visual impairment								
and blindness	1.38	1.21	0.48	0.68	0.82	0.81	1.18	0.75

						Mixed		Macular
	Very extensive		_	Respiratory	CVD +	including	Healthy +	degeneration
Condition	morbidity	Migraine	Respiratory	w/o other	diabetes	cancer	rhinitis	+ diabetes
Addisons disease	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Allergic and chronic								
rhinitis	0.00E+00	5.20E-58	0.00E+00	0.00E+00	0.00E+00	0.00E+00	0.00E+00	3.40E-173
Asbestosis	1.00E-06	8.97E-01	1.00E+00	1.00E+00	1.00E+00	1.00E+00	7.88E-02	1.00E+00
Asthma	1.90E-14	2.34E-213	0.00E+00	0.00E+00	1.40E-270	0.00E+00	0.00E+00	5.89E-08
Atrial fibrillation	4.36E-53	5.07E-05	6.81E-03	4.06E-07	3.04E-28	6.59E-07	1.16E-19	1.00E+00
Benign neoplasm of brain and other								
parts of central	4.005.00	1.005.00	1.005.00	4.005.00	4.005.00	0.005.00	0.475.04	4.005.00
nervous system	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	2.99E-02	3.1/E-01	1.00E+00
Bronchiectasis	5.93E-02	3.71E-05	1.07E-21	2.19E-17	1.42E-02	4.47E-01	2.46E-10	1.00E+00
COPD	3.07E-67	2.35E-15	9.73E-102	8.51E-120	1.29E-01	6.00E-62	1.24E-118	1.00E+00
Cardiomyopathy	1.76E-04	7.04E-02	1.00E+00	1.00E+00	1.29E-04	1.00E+00	2.53E-01	1.00E+00
Cerebral Palsy	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	7.57E-01	1.00E+00	1.00E+00
Chronic liver disease	2.75E-10	6.49E-01	1.00E+00	1.00E+00	1.67E-03	2.50E-03	9.20E-04	1.00E+00
Chronic renal disease	2.86E-113	4.51E-05	1.96E-05	4.12E-17	2.02E-41	1.88E-21	7.15E-33	1.00E+00
Coeliac disease	1.00E+00	1.00E+00	4.77E-01	1.00E+00	5.55E-12	1.18E-06	1.00E+00	1.00E+00
Conduction disorders and other arrhythmias	7.24E-05	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	3.14E-10	1.00E+00
Coronary heart disease	0.00E+00	4.70E-28	5.24E-17	9.89E-36	1.39E-171	7.11E-119	5.50E-137	1.00E+00
Cystic Fibrosis	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Dementia	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Diabetes NOS	6.64E-11	1.00E+00	1.00E+00	1.00E+00	7.33E-12	2.15E-04	3.84E-07	1.00E+00
Diverticular disease of intestine (acute	0.245 120	1.005+00	1.005±00	5 545 02	2 265 00	1.005+00	1 005 22	1.005+00
and chronic)	9.042-109	1.000+00	T.00E+00	5.54E-03	2.202-09	1.00E+00	1.905-23	1.000+00

Supplementary Table 2.d. Adjusted *p*-values values for *whole*-cohort clusters.

Down's syndrome	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.44E-01	1.00E+00	1.00E+00
Epilepsy	1.00E+00	1.00E+00	1.00E+00	1.00E+00	2.71E-05	1.06E-26	7.46E-08	1.00E+00
Erectile dysfunction	2.55E-104	3.35E-41	1.45E-15	1.77E-15	3.70E-19	2.46E-01	2.32E-27	5.01E-02
Fatty Liver	9.12E-28	1.00E+00	6.44E-02	4.42E-01	1.00E+00	3.28E-13	3.21E-01	1.00E+00
Gastro- oesophageal reflux, gastritis and similar	0.00E+00	1.00E+00	1.00E+00	5.25E-44	0.00E+00	7.78E-28	4.08E-119	1.70E-20
Glaucoma	6.27E-06	9.19E-03	2.85E-02	6.19E-04	4.75E-03	4.24E-05	9.70E-14	5.77E-13
Gout	7.73E-131	2.32E-37	4.51E-09	2.28E-14	2.46E-52	7.52E-07	3.29E-37	1.00E+00
HIV	1.00E+00	1.00E+00	1.00E+00	1.00E+00	4.24E-01	1.27E-03	1.00E+00	1.00E+00
Haematological malignancies	1.00E+00	6.07E-01	1.00E+00	1.00E+00	1.00E+00	4.93E-11	8.21E-07	1.00E+00
Hearing loss	2.12E-46	3.62E-04	4.36E-02	3.38E-02	1.00E+00	6.38E-14	1.69E-27	1.00E+00
Heart failure	1.14E-63	2.80E-06	1.00E+00	3.33E-04	2.28E-27	1.94E-21	2.26E-19	1.00E+00
Heart valve disorders	6.49E-20	1.00E+00	3.89E-02	4.96E-07	6.86E-08	1.00E+00	2.83E-15	1.00E+00
Hyperplasia of prostate	1.91E-56	1.02E-30	3.24E-09	2.32E-06	1.00E+00	6.54E-14	6.21E-16	1.00E+00
Hypertension	0.00E+00	1.04E-85	5.84E-71	0.00E+00	0.00E+00	0.00E+00	0.00E+00	1.00E+00
Hypo or hyperthyroidism	5.80E-06	1.00E+00	1.00E+00	3.97E-03	1.52E-14	1.96E-65	2.95E-22	1.00E+00
Immunodeficiencies	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Inflammatory arthritis and other inflammatory conditions	7.01E-77	1.00E+00	1.00E+00	1.29E-05	1.15E-21	1.71E-06	9.72E-16	1.00E+00
Inflammatory bowel disease	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.49E-11	3.32E-22	2.09E-01	1.00E+00
Iron and vitamin deficiency anaemia	4.11E-16	6.14E-07	1.00E+00	2.97E-04	1.33E-35	8.77E-36	3.23E-19	1.00E+00
Irritable bowel syndrome	1.70E-12	7.68E-57	2.34E-09	1.71E-01	3.08E-214	1.51E-20	1.00E+00	4.78E-03
Macular degeneration	8.53E-06	1.00E+00	1.00E+00	3.79E-35	1.90E-138	1.02E-270	1.31E-04	0.00E+00
Meniere disease	1.37E-04	3.15E-01	1.00E+00	1.00E+00	1.18E-03	1.00E+00	7.08E-01	1.00E+00

	3.69136621242e-							
Migraine	312	0.00E+00	7.75E-05	4.04E-280	0.00E+00	0.00E+00	0.00E+00	1.19E-42
Motor neuron								
disease	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Multiple sclerosis	2.03E-04	1.00E+00	1.00E+00	1.00E+00	3.30E-02	9.49E-20	5.51E-02	1.00E+00
Myasthenia gravis	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Non-acute cystitis	6.79E-01	7.45E-01	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Non-melanoma				_				
skin malignancies	7.32E-01	9.62E-04	5.58E-05	2.55E-03	3.77E-02	2.71E-62	7.53E-17	1.00E+00
Osteoarthritis (excl	0.005.00	0 175 00	1.045.04	1 015 54	0.005.00		1 005 150	F 10F 00
spine)	0.00E+00	8.1/E-03	1.94E-24	1.21E-54	0.00E+00	2.03E-08	1.08E-153	5.19E-20
vertebral crush								
fractures	1.74E-15	1.00E+00	1.00E+00	1.00E+00	1.10E-32	4.49E-28	4.10E-16	1.00E+00
Parkinson's								
disease	1.00E+00	1.11E-01	1.00E+00	1.00E+00	1.00E+00	2.10E-03	1.88E-01	1.00E+00
Peptic ulcer								
disease	4.57E-216	9.20E-01	4.88E-10	2.31E-04	2.08E-37	2.07E-04	6.11E-38	1.00E+00
Peripheral arterial	1 005 07	2 705 05	4 445 00	0.105.00	7 005 10		0 105 00	1.005.00
disease Dariaharahar	1.02E-67	3.78E-05	4.44E-03	6.16E-03	7.62E-18	4.61E-10	8.13E-23	1.00E+00
Peripheral or								
neuropathy	3.17E-47	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.85E-02	4.69E-10	1.00E+00
Postviral fatique								
syndrome,								
neurasthenia and								
fibromyalgia	2.63E-07	3.09E-13	5.80E-08	1.00E+00	4.27E-47	1.00E+00	1.00E+00	1.00E+00
Primary pulmonary	4 995 94	4 995 99	4 995 99	4 995 99		4 4 4 5 4 4 4	4 4 9 5 9 9	4 995 99
hypertension	1.20E-01	1.00E+00	1.00E+00	1.00E+00	3.13E-01	1.00E+00	1.12E-02	1.00E+00
Psoriasis	1.00E+00	1.23E-02	2.74E-02	3.60E-03	2.60E-10	1.22E-37	1.00E+00	1.00E+00
Sarcoidosis	1.00E+00	3.37E-01	1.00E+00	1.00E+00	1.00E+00	1.13E-01	6.02E-01	1.00E+00
Sickle-cell anaemia	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Sleep apnoea	2.00E-26	1.25E-01	1.00E+00	1.78E-02	1.00E+00	4.34E-09	1.00E+00	1.00E+00
Solid organ								
malignancies	1.28E-08	2.36E-02	2.27E-09	1.78E-02	1.31E-08	6.29E-129	9.89E-45	1.00E+00
Spinal stenosis	3.18E-23	1.00E+00	1.00E+00	5.99E-02	6.10E-03	1.00E+00	2.59E-04	1.00E+00

Stroke	5.88E-82	8.94E-04	2.38E-05	4.64E-13	3.73E-50	1.11E-33	6.00E-52	1.00E+00
Thalassaemia	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Transient								
ischaemic attack	3.56E-72	1.77E-02	4.14E-04	1.71E-10	7.73E-14	9.68E-15	1.74E-31	1.00E+00
Tuberculosis	2.44E-07	5.74E-01	1.00E+00	1.00E+00	2.71E-02	5.21E-06	2.43E-06	1.00E+00
Type 1 diabetes	1.00E+00	1.51E-02	1.00E+00	1.00E+00	1.98E-06	1.00E+00	2.06E-02	2.67E-05
Type 2 diabetes	1.83E-302	6.56E-52	6.79E-04	7.88E-35	2.13E-226	7.51E-160	8.32E-70	8.81E-04
Urinary								
Incontinence	5.02E-23	5.95E-20	2.53E-06	1.00E+00	8.15E-79	8.00E-08	9.51E-11	1.00E+00
Visual impairment								
and blindness	2.88E-02	1.00E+00	1.00E+00	2.66E-01	1.82E-01	6.64E-01	1.00E+00	5.24E-33

	Very						Mixed	
	extensive	Extensive	_	D: ()	MOK	CVD +	including	Healthy +
Condition	morbidity	morbidity	Respiratory	Digestive	MSK	diabetes	cancer	rhinitis
Addisons disease	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Allergic and chronic	0.00E+00	1 75E-156	0.00E+00	8 91 F-07	0.00E+00	0.00E+00	0.00E+00	0.00E+00
Ashestosis	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Asthma	5.35E-89	5.87E-12	0.00E+00	8.88E-05	4.08E-157	9.84E-263	3.64E-48	0.00E+00
Atrial fibrillation	1.79E-08	3.79E-01	2.40E-02	1.00E+00	4.84E-02	7.02E-12	4.44E-05	4.27E-27
Benign neoplasm of								
brain and other								
nervous system	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	2.79E-02
Bronchiectasis	1.17E-01	1.00E+00	1.35E-11	1.00E+00	1.00E+00	3.02E-01	1.00E+00	7.75E-06
COPD	2.00E-16	2.62E-08	9.57E-34	9.94E-02	1.00E+00	4.85E-01	1.95E-03	5.93E-54
Cardiomyopathy	4.66E-01	1.00E+00	1.00E+00	1.00E+00	1.00E+00	3.16E-03	1.00E+00	4.06E-02
Cerebral Palsy	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Chronic liver	1.005.00	4 005 01	1.005.00	1.005+00	1.005.00	4 775 01	2 025 02	0.015.00
disease Chronic rend	1.00E+00	4.20E-01	1.00E+00	1.00E+00	1.00E+00	4.77E-01	3.03E-02	8.21E-02
disease	3.76E-10	2.50E-10	1.41E-04	6.98E-02	1.00E+00	1.98E-39	1.90E-17	1.01E-42
Coeliac disease	1.00E+00	1.00E+00	1.00E+00	2.14E-01	2.93E-02	5.10E-06	3.11E-03	1.00E+00
Conduction								
disorders and other	7 525 01	0.665.01	1 005+00	1 005+00	1 005+00	1 005+00	1 005+00	2 01 5 06
arrnythmias	7.53E-01	9.002-01	1.002+00	1.002+00	1.002+00	1.002+00	1.002+00	3.91E-00
disease	7.94E-67	8.72E-40	4.46E-09	3.74E-04	8.49E-02	3.18E-97	1.09E-77	1.19E-135
Cystic Fibrosis	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Dementia	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Diabetes NOS	7.72E-02	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.63E-04	8.21E-01	2.76E-05
Diverticular disease								
of intestine (acute	1 415 00	0.015.40	0.005.01	0.045.00	0.505.01	1.005.00	1 005 05	1 01 5 44
and chronic)	1.41E-62	2.61E-42	2.00E-01	2.34E-02	2.58E-01	1.00E+00	1.06E-05	1.21E-44

Supplementary Table 2.e. Adjusted *p*-values values for *women-only* clusters.

Down's syndrome	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	7.42E-04	1.00E+00
Epilepsy	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	6.90E-03	8.04E-11	2.28E-03
Erectile dysfunction	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Fatty Liver	3.51E-17	9.03E-12	1.00E+00	1.00E+00	1.00E+00	2.85E-01	2.73E-10	7.92E-08
Gastro-								
oesophageal reflux,	4 405 453		4 995 99				4 995 99	0.055.400
gastritis and similar	4.43E-157	0.00E+00	1.00E+00	0.00E+00	0.00E+00	1.14E-26	1.00E+00	3.35E-109
Glaucoma	1.00E+00	5.89E-02	3.75E-03	1.00E+00	1.00E+00	1.05E-02	1.00E+00	3.04E-09
Gout	5.08E-05	8.97E-04	1.00E+00	2.47E-01	1.17E-02	8.67E-06	3.64E-12	2.58E-16
HIV	1.00E+00	1.00E+00	1.00E+00	1.00E+00	7.20E-06	1.00E+00	6.82E-06	1.00E+00
Haematological								
malignancies	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.66E-03	2.47E-06
Hearing loss	6.49E-14	1.91E-05	1.00E+00	1.00E+00	1.76E-02	7.82E-02	1.00E+00	1.43E-16
Heart failure	2.07E-05	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.04E-07	3.05E-07	5.41E-16
Heart valve								
disorders	3.28E-05	1.00E+00	1.40E-03	1.00E+00	1.00E+00	1.11E-05	1.00E+00	2.14E-14
Hyperplasia of								
prostate	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Hypertension	0.00E+00	6.66E-02	1.56E-111	1.00E+00	1.21E-11	0.00E+00	0.00E+00	0.00E+00
Hypo or	0 755 05	4 7 4 5 0 0	4 705 04	4 005.00	4.005.00	4.005.00	4 005 47	0.045.44
hyperthyroidism	6.75E-05	4./4E-02	1.78E-04	1.00E+00	1.00E+00	1.00E+00	1.60E-47	2.91E-41
Immunodeficiencies	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Inflammatory								
arthritis and other								
Inflammatory	3 725-26	1 /9E-27	2 585-03	1 005+00	9 10E-22	1.085-08	2 18E-01	5 8/E-20
Inflammatory bowel	3.72L-20	1.401-27	2.301-03	1.002+00	9.10L-22	1.002-00	2.102-01	J.04L-23
disease	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	6.41E-05	1.00E-10	5.59E-01
Iron and vitamin								
deficiency anaemia	4.65E-01	5.20E-05	1.00E+00	2.67E-01	1.69E-10	1.96E-07	2.51E-48	1.37E-10
Irritable bowel								-
syndrome	0.00E+00	5.81E-02	1.81E-21	4.93E-02	1.61E-152	5.78E-170	1.14E-23	1.80E-02
Macular								
degeneration	7.88E-06	1.00E+00	1.00E+00	1.00E+00	1.00E+00	6.52E-01	1.00E+00	2.34E-10
Meniere disease	4.18E-10	1.82E-04	1.00E+00	1.00E+00	1.00E+00	9.00E-01	1.00E+00	4.13E-02
Migraine	9.45E-27	5.56E-02	1.00E+00	2.97E-01	1.65E-08	3.45E-34	8.61E-77	8.28E-09

Motor neuron								
disease	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Multiple sclerosis	1.00E+00	8.73E-01	1.00E+00	1.00E+00	3.68E-02	1.55E-01	1.78E-16	1.00E+00
Myasthenia gravis	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Non-acute cystitis	8.63E-01	1.30E-01	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Non-melanoma								
skin malignancies	1.00E+00	1.00E+00	2.52E-02	1.00E+00	1.00E+00	5.43E-03	4.07E-21	1.82E-11
Osteoarthritis (excl spine)	0.00E+00	0.00E+00	5.75E-113	1.17E-75	0.00E+00	0.00E+00	0.00E+00	0.00E+00
Osteoporosis and vertebral crush fractures	8.66E-08	2.80E-11	1.00E+00	1.00E+00	6.12E-08	1.13E-11	1.83E-04	1.46E-24
Parkinson's disease	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Peptic ulcer disease	1.53E-12	6.17E-89	4.68E-01	0.00E+00	1.19E-09	1.33E-46	2.01E-32	1.95E-57
Peripheral arterial disease	5.40E-06	6.40E-05	5.88E-01	1.00E+00	1.00E+00	2.17E-03	9.37E-02	4.79E-11
Peripheral or autonomic neuropathy	2.10E-11	2.14E-07	1.00E+00	6.75E-01	1.17E-01	1.00E+00	1.00E+00	1.39E-12
Postviral fatigue syndrome, neurasthenia and fibromyalgia	1.66E-49	1.30E-16	1.00E+00	1.00E+00	1.00E+00	7.74E-24	1.00E+00	6.57E-02
Primary pulmonary hypertension	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.01E-01	1.00E+00	1.35E-02
Psoriasis	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	5.09E-09	3.53E-14	2.74E-03
Sarcoidosis	1.00E+00	6.80E-01	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.12E-01
Sickle-cell anaemia	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Sleep apnoea	1.24E-14	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.39E-05	1.09E-03
Solid organ							_	
malignancies	1.00E+00	6.88E-02	1.67E-09	1.00E+00	1.00E+00	1.77E-01	5.98E-72	1.54E-29
Spinal stenosis	2.51E-08	9.76E-06	1.00E+00	1.00E+00	5.05E-12	3.66E-04	5.89E-05	1.64E-07
Stroke	1.72E-12	1.12E-04	1.01E-01	8.88E-01	1.00E+00	3.59E-26	2.89E-11	1.70E-37
Thalassaemia	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00

Transient ischaemic attack	1.83E-11	1.84E-09	1.67E-03	1.00E+00	1.00E+00	2.17E-11	2.00E-08	9.24E-23
Tuberculosis	1.17E-02	2.46E-01	1.00E+00	1.00E+00	2.06E-01	1.00E+00	1.00E+00	3.69E-03
Type 1 diabetes	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.41E-03	1.00E+00	3.33E-01
Type 2 diabetes	2.64E-53	4.53E-09	3.89E-02	1.00E+00	1.00E+00	2.05E-114	4.09E-85	5.09E-104
Urinary								
Incontinence	1.49E-54	1.56E-22	1.00E+00	1.00E+00	1.00E+00	3.10E-21	3.91E-03	3.48E-22
Visual impairment								
and blindness	5.35E-03	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	3.29E-01

	Very		Respiratory +				Mixed	
	extensive		gout + male		CVD +	CVD + CKD +	including	Healthy +
Condition	morbidity	MSK + others	genitourinary	Digestive	diabetes	gout	cancer	rhinitis
Addisons disease	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Allergic and chronic	_							
rhinitis	6.13E-183	3.76E-37	2.01E-194	5.98E-20	9.71E-92	4.23E-140	0.00E+00	0.00E+00
Asbestosis	1.00E+00	3.06E-03	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.76E-02
Asthma	3.09E-20	6.44E-09	0.00E+00	1.49E-05	3.80E-19	5.37E-59	1.85E-01	9.33E-123
Atrial fibrillation	2.75E-13	1.00E+00	1.00E+00	1.00E+00	3.04E-05	1.90E-13	1.14E-04	4.53E-41
Benign neoplasm of								
brain and other								
parts of central	0 105 01	1.005.00	1.005.00	1.005.00	1.005.00	1.005.00	1.005.00	1.005.00
nervous system	9.12E-01	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Bronchiectasis	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
COPD	4.40E-03	5.04E-17	5.98E-09	1.62E-02	1.00E+00	1.00E+00	7.74E-02	1.41E-28
Cardiomyopathy	1.00E-01	1.00E+00	8.86E-01	1.00E+00	1.00E+00	4.34E-03	2.48E-01	1.24E-02
Cerebral Palsy	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	4.59E-01
Chronic liver		4 995 99	4 995 99			4 4 4 5 4 4 4	0.005.04	0.005.04
disease	4.81E-01	1.00E+00	1.00E+00	1.31E-04	7.70E-01	1.00E+00	6.82E-01	8.08E-04
Chronic renal	0.055.00	1.005.00		1.005.00		1 145 22		
disease	9.23E-29	1.00E+00	1.002+00	1.00E+00	0.232-00	1.14E-33	0.00E-04	2.30E-00
Coeliac disease	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	6.30E-04	1.00E+00
Conduction								
arrhythmias	1.00F+00	1.00F+00	1.00F+00	1.00F+00	1.00F+00	1.00F+00	1.00F+00	8.64F-07
Coronary heart	1.002.00	1.002.00	1.002.00	1.002.00	1.002.00	1.002.00	1.002.00	0.042 07
disease	3.44E-93	2.63E-07	1.00E+00	1.00E+00	2.37E-82	4.01E-22	1.85E-49	3.54E-284
Cystic Fibrosis	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Dementia	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Diabetes NOS	3.02E-16	1.00E+00	1.00E+00	1.00E+00	2.82E-03	1.00E+00	3.20E-02	4.10E-15
Diverticular disease								
of intestine (acute			_					
and chronic)	2.44E-04	1.29E-13	6.12E-02	1.08E-01	8.16E-02	3.60E-02	1.00E+00	5.96E-37

Supplementary Table 2.f. Adjusted *p*-values values for *men-only* clusters.

Down's syndrome	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Epilepsy	1.00E+00	1.00E+00	1.00E+00	1.00E+00	5.43E-02	1.00E+00	1.33E-18	3.89E-05
Erectile dysfunction	0.00E+00	9.81E-90	1.66E-138	6.37E-27	0.00E+00	5.60E-177	0.00E+00	3.22E-167
Fatty Liver	2.03E-03	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	3.17E-02	4.08E-03
Gastro-								
oesophageal reflux,	0 705 00	0.575.00	4.005.00	5 005 170	4 405 44	4.005.00	0.005.00	7 005 00
gastritis and similar	6.79E-08	3.57E-28	1.00E+00	5.06E-1/3	1.46E-41	1.00E+00	3.20E-29	7.92E-83
Glaucoma	1.18E-01	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.55E-03	1.63E-16
Gout	4.19E-14	1.37E-81	4.61E-279	8.45E-25	0.00E+00	0.00E+00	0.00E+00	3.34E-159
HIV	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.07E-03	1.00E+00
Haematological								
malignancies	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	3.61E-01	7.23E-03	2.17E-04
Hearing loss	2.99E-07	1.83E-16	1.00E+00	1.00E+00	1.02E-04	1.00E+00	1.82E-06	1.16E-45
Heart failure	1.74E-13	1.00E+00	1.00E+00	1.00E+00	9.80E-06	1.37E-14	1.23E-13	1.86E-38
Heart valve								
disorders	1.98E-03	1.00E+00	1.00E+00	1.00E+00	4.55E-02	2.83E-01	1.00E+00	5.66E-19
Hyperplasia of	0.405.00	0.045.05	4.445.00	4.005.00	4.405.00	0.075.04	4 405 00	0.405.55
prostate	2.12E-32	9.04E-25	4.11E-02	1.00E+00	4.16E-09	2.67E-01	4.42E-08	3.16E-55
Hypertension	0.00E+00	1.33E-13	1.05E-17	9.06E-14	0.00E+00	3.42E-274	0.00E+00	0.00E+00
Hypo or	2 205 22	1.005.00	1.005.00	1.005.00	1.005.00	1.005.00	1 5 4 5 00	0.005.10
hyperthyroidism	3.29E-02	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.54E-06	9.20E-10
Immunodeficiencies	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Inflammatory								
arthritis and other								
conditions	1 00F+00	3 60F-39	1 00F+00	1 00F+00	7 73F-09	1.32E-01	1 00F+00	1 28F-26
Inflammatory bowel	1.002.00	0.002 00	1.002.00	1.002.00	7.702.00	1.022 01	1.002.00	1.202 20
disease	1.00E+00	1.00E+00	1.00E+00	1.00E+00	9.15E-05	1.00E+00	3.58E-09	1.00E+00
Iron and vitamin								
deficiency anaemia	6.99E-03	1.00E+00	1.00E+00	2.43E-07	1.76E-04	1.00E+00	1.32E-01	4.74E-11
Irritable bowel								
syndrome	1.00E+00	1.00E+00	1.00E+00	1.05E-04	9.36E-18	5.31E-04	1.26E-23	1.00E+00
Macular	4.075.00	4.005.00	4.005.00	4.005.00	1.005.00	4.005.00		0 505 00
degeneration	4.9/E-03	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	7.55E-01	2.50E-08
Meniere disease	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.37E-01	4.38E-05
Migraine	1.00E+00	1.00E+00	1.00E+00	1.00E+00	7.04E-06	4.40E-04	5.62E-33	5.49E-01

Motor neuron								
disease	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Multiple sclerosis	2.13E-05	3.17E-03	1.00E+00	1.00E+00	1.00E+00	1.00E+00	3.29E-02	1.00E+00
Myasthenia gravis	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Non-acute cystitis	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Non-melanoma								
skin malignancies	1.00E+00	1.00E+00	1.00E+00	9.24E-01	5.51E-02	1.00E+00	1.92E-20	3.20E-14
Osteoarthritis (excl spine)	1.00E+00	0.00E+00	7.30E-01	4.23E-256	0.00E+00	1.00E+00	0.00E+00	0.00E+00
Osteoporosis and								
vertebral crush							_	
fractures	1.48E-01	2.71E-03	1.00E+00	1.00E+00	4.14E-03	1.00E+00	3.59E-01	7.54E-05
Parkinson's	1 205 02	1 005+00	1.005+00	1 005+00	1.005+00	1.005+00	2 21E 01	2 705 02
Doptic ulcor	1.202-03	1.002+00	1.002+00	1.002+00	1.002+00	1.002+00	2.312-01	2.79E-02
disease	4.04E-02	1.91E-06	1.00E+00	0.00E+00	0.00E+00	4.13E-01	0.00E+00	4.33E-295
Peripheral arterial								
disease	1.32E-30	1.00E+00	1.00E+00	1.00E+00	1.20E-02	1.00E+00	1.03E-09	4.35E-42
Peripheral or								
autonomic	2 08E-23	3 60E-05	1 005+00	1 00E±00	7 33E-01	1 00E±00	5 25E-03	2 14E-20
Postviral fatique	2.301-23	3.002-03	1.002+00	1.002+00	7.551-01	1.002100	5.252-05	2.14L-20
syndrome								
neurasthenia and								
fibromyalgia	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.30E-08	1.00E+00	5.77E-03	1.00E+00
Primary pulmonary								
hypertension	1.00E+00	1.00E+00	1.00E+00	1.00E+00	6.68E-01	1.00E+00	1.00E+00	1.00E+00
Psoriasis	1.00E+00	1.00E+00	1.00E+00	1.00E+00	2.50E-06	1.00E+00	8.29E-22	4.75E-01
Sarcoidosis	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	2.67E-06	1.00E+00
Sickle-cell anaemia	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00
Sleep apnoea	4.24E-10	1.27E-02	1.00E+00	1.00E+00	1.00E+00	4.55E-01	9.01E-03	3.89E-13
Solid organ			4 9 9 5 9 9			1 005 00		
malignancies	5.64E-34	1.00E+00	1.00E+00	1.00E+00	2.33E-07	1.00E+00	1.37E-16	1.92E-41
Spinal stenosis	1.00E+00	5.52E-20	1.00E+00	1.00E+00	3.83E-03	1.00E+00	1.00E+00	9.90E-07
Stroke	7.00E-21	1.00E+00	1.00E+00	1.00E+00	5.25E-26	3.41E-08	5.75E-16	1.67E-73
Thalassaemia	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00

Transient ischaemic attack	2.58E-14	1.00E+00	1.00E+00	1.00E+00	2.36E-07	1.36E-05	2.85E-06	7.76E-50
Tuberculosis	1.00E+00	1.00E+00	1.00E+00	1.00E+00	7.21E-01	1.00E+00	5.29E-09	1.57E-07
Type 1 diabetes	7.95E-17	2.28E-03	1.00E+00	1.00E+00	1.00E+00	7.84E-02	1.00E+00	9.82E-05
Type 2 diabetes	1.15E-233	4.32E-01	1.00E+00	1.00E+00	4.43E-55	8.48E-17	7.10E-90	4.78E-204
Urinary								
Incontinence	2.84E-14	3.77E-01	1.00E+00	1.00E+00	2.08E-05	2.68E-01	1.00E+00	8.49E-02
Visual impairment								
and blindness	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00	1.00E+00